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Abstract—Obesity, the insulin resistance syndrome, and atherosclerosis are closely linked and may all be determinants of an
increased acute-phase response. In this study, we examined the relationship of C-reactive protein (CRP) with measures of
obesity, variables of the insulin resistance syndrome, and intima-media thickness of the common carotid arteries in 186
healthy, middle-aged women selected from the general population. Associations were assessed by regression analysis. CRP
was strongly associated with body mass index (BMI) and waist circumference. CRP was also associated with other variables
of the insulin resistance syndrome, including blood pressure, insulin, high density lipoprotein cholesterol, triglycerides,
apolipoprotein A1 (inversely), plasminogen activator inhibitor-1 antigen, and tissue-type plasminogen activator antigen.
Associations between CRP and the variables of the insulin resistance syndrome disappeared after controlling for BMI but
remained significant for plasminogen activator inhibitor-1 antigen only. The association of CRP with common carotid artery
intima-media thickness was weak and limited to ever-smokers. BMI explained 29.7% of the variance of CRP, whereas
common carotid artery intima-media thickness explained only 3.7%. The results of this population-based study indicate that
adiposity is strongly associated with CRP in healthy, middle-aged women. In this population, BMI accounted for the
relationship between CRP and other variables of the insulin resistance syndrome. Further studies should determine whether
losing weight ameliorates the inflammatory state. (Arterioscler Thromb Vasc Biol. 1999;19:1986-1991.)
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Recent data suggest that inflammation is involved in athero-genesis.1,2 C-reactive protein (CRP), a major acute-phase
protein, has been associated with the presence and severity of
atherosclerosis3 and has been found to predict cardiac events in
subjects with4–6 and without7–9 prevalent cardiovascular disease.
Raised concentrations of inflammatory mediators may reflect
inflammation in the arterial wall associated with atherosclerosis
but may also be causally involved in the disease process.10,11
Sources of inflammation include infections10–12 and smoking.13
Moreover, levels of obesity have been shown to be associated
with low-grade inflammation.14,15
Recent data also indicate that the insulin resistance syn-
drome is accompanied by an increased acute-phase re-
sponse.16,17 A link between the insulin resistance syndrome
and the inflammatory state is further suggested by increased
levels of the acute-phase proteins plasminogen activator
inhibitor-1 (PAI-1) and fibrinogen in the insulin resistance
syndrome18–20 and by the finding that dyslipidemia in the
insulin resistance syndrome and during the acute-phase re-
sponse shows strong similarities.21–23
Obesity, the insulin resistance syndrome, and atheroscle-
rotic disease are closely linked and may all be determinants of
an increased acute-phase response. However, it is not clear
whether these factors are independently associated with the
inflammatory state. Previous studies on associations between
CRP level as a measure of inflammation and cardiovascular
risk factors were conducted in middle-aged men and elderly
men and women, all of whom are at relatively high risk for
atherosclerosis.14,15 Atherosclerosis and smoking are poten-
tial sources of inflammation and possibly obscure the relation
of CRP with other risk factors.
In the present study, we investigated the relationship between
CRP and measures of obesity, the insulin resistance syndrome,
and subclinical atherosclerosis in a population of healthy,
middle-aged women with a low exposure to tobacco smoke.
Methods
Study Population
We studied a population of 186 women, aged 43 to 55 years, selected
from the general population and participating in a study on the
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cardiovascular effects of natural menopause. Women were selected
from respondents to a mailed questionnaire about menopause, which
was sent to all women aged 40 to 60 years living in the town of
Zoetermeer, the Netherlands (N512 675). Women were considered
premenopausal if they had experienced 1 or more regular bleeding
episodes in the past 12 months and were free from climacteric
symptoms, defined as perspiration and/or hot flushes. Women were
considered postmenopausal if their menses had ceased naturally for
at least 12 months. Exclusion criteria were diabetes mellitus,
prevalent clinical cardiovascular disease, and use of antihypertensive
medication or cholesterol-lowering drugs. Women reporting use of
female hormones (hormone replacement therapy or oral contracep-
tives) within 6 months before the clinical examination were ex-
cluded, as were subjects currently smoking 5 or more cigarettes per
day. Of the eligible subjects, 93 premenopausal and 93 postmeno-
pausal age-matched women were selected (response rate 76% of
eligible and invited women). All women gave written informed
consent, and the study was approved by the medical ethics commit-
tee of the Erasmus University Medical School.
Measurements
During a visit at the research center, a medical history was taken by
a physician. Height, weight, and waist and hip circumferences were
measured while the subjects wore indoor clothes without shoes.
Body mass index (BMI, weight divided by height squared) and
waist-to-hip ratio (WHR) were computed. Cigarette smoking history
was obtained by a standardized questionnaire. Blood pressure was
assessed with a DINAMAP automatic blood pressure recorder
(Critikon, Inc). After a 5-minutes rest in the supine position, blood
pressure was measured 4 times at the right upper arm with an
appropriately sized cuff, and the mean was used in the analyses.
Venous blood samples were drawn from each subject after a 12-hour
fast. The samples were stored at 280°C. Total cholesterol was
measured with an automated enzymatic method using the CHOD-
PAP high-performance reagent kit from Boehringer Mannheim.
HDL cholesterol was measured by the phosphotungstate method.
LDL cholesterol was computed by the Friedewald formula.24 Tri-
glycerides were determined by using a reagent kit from Boehringer
Mannheim after enzymatic hydrolysis of the triglycerides and
subsequent determination of liberated glycerol by colorimetry. No
correction was made for serum free glycerol. Apolipoproteins A1
and B were measured by an automated turbidimetric immunoassay
with reagent kits from Orion Diagnostics. Glucose was enzymati-
cally determined by the hexokinase method (Instruchemie). Serum
insulin was determined by metric assay (Biosource Diagnostics).
This assay has no cross-reactivity with either proinsulin or
C-peptide. PAI-1 antigen and tissue-type plasminogen activator
(tPA) antigen levels were determined by ELISA (Innotest PAI-1,
Innogenetics NV, and Imulyse, Biopool, respectively). CRP was
measured by an in-house ELISA with rabbit anti-CRP (Dako) as the
catching and tagging antibody.25 Intra-assay and interassay CVs for
CRP were 3.8% and 4.7%, respectively. Fasting insulin levels were
used as a measure of insulin resistance.26 In addition, insulin
sensitivity was calculated according to the formula of the homeosta-
sis model assessment method (HOMA): insulin resistance5fasting
insulin3fasting glucose/22.5.27
Carotid Artery Intima-Media Thickness (IMT)
Common carotid artery IMT was used as an indicator of generalized
atherosclerosis.28 Ultrasonography of the right common carotid
artery was performed with a 7.5-MHz linear-array transducer (ATL
UltraMark IV) as described in detail previously.29 For each individ-
ual, the common carotid artery IMT was determined as the average
of near- and far-wall measurements. Carotid artery IMT measure-
ments have been shown to be reproducible.30 In short, mean
differences (and SDs) in far-wall IMT of the common carotid arteries
between paired measurements of sonographers, readers, and visits
were 0.040 mm (0.07), 0.069 mm (0.04), and 0.071 mm (0.09),
respectively. The intraclass correlation coefficients were 0.63, 0.88,
and 0.74, respectively. These results are in agreement with the
reproducibility of IMT measurements found in other studies.31 In the
present study, all measurements were conducted by 1 sonographer
and 1 reader.
Statistical Analysis
The clinical and biochemical features of the population are presented
as mean6SD, median (and interquartile range) for variables with a
skewed distribution, or percentages. Because the distribution of CRP
was highly skewed, it was natural-log–transformed for all analyses.
The strength of the associations between CRP and clinical and
biochemical variables was assessed by linear regression of ln CRP on
each variable separately, adjusted for age. Because strong associa-
tions were found between CRP and measures of obesity, we adjusted
for them in additional models. Regression analysis was further used
to estimate the explained proportion of variance in CRP (R2). The
difference in CRP between premenopausal and postmenopausal
women adjusted for age and measures of obesity was studied with
regression analysis. A probability value ,0.05 (2-tailed test) was
considered significant. SPSS 7.5 for Windows was used for all
analyses.
Results
Characteristics of the population are described in Table 1.
BMI ranged from 16.8 to 41.1 kg/m2; 42 subjects had a BMI
.27 kg/m2. CRP varied from 0.05 to 14.38 mg/L; 2 subjects
had values .10 mg/L (10.70 and 14.38 mg/L), the cutpoint
TABLE 1. Clinical and Biochemical Characteristics of 186
Middle-Aged Women
Variable All Subjects
Age, y 50.962.3
BMI, kg/m2 24.964.0
Waist circumference, cm 81.569.5
Hip circumference, cm 105.768.6
WHR, cm/cm 0.7760.05
Smoking status, %
Never 53.2
Past 40.3
Current* 6.5
Systolic blood pressure, mm Hg 121614
Diastolic blood pressure, mm Hg 68610
Hypertension, %† 2.2
Glucose, mmol/L 5.560.6
Insulin, picomol/L‡ 44.0 (32.0–59.0)
HOMA, picomol3mmol/L2‡§ 10.8 (7.7–15.5)
Total cholesterol, mmol/L 6.261.0
HDL cholesterol, mmol/L 1.660.4
LDL cholesterol, mmol/L 4.160.9
Triglycerides, mmol/L‡\ 1.0 (0.8–1.3)
Apolipoprotein A1, mg/dL 154.5631.6
Apolipoprotein B, mg/dL 102.0626.3
PAI-1 antigen, ng/mL‡ 53.0 (34.0–85.3)
tPA antigen, ng/mL 6.362.4
CRP, mg/L‡ 0.68 (0.33–1.44)
Common carotid artery IMT, mm 0.6160.09
Data are mean6SD, median (interquartile range) for variables with skewed
distributions, or percentages.
*Subjects who smoked 5 or more cigarettes a day were excluded from study
participation.
†Hypertension was defined as systolic blood pressure $160 mm Hg and/or
diastolic blood pressure $95 mm Hg.
‡Skewed data.
§HOMA5fasting insulin3fasting glucose/22.5.
\Highest level of triglycerides was 3.80 mmol/L.
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generally used to identify clinically relevant inflammation.32
Fasting insulin levels ranged from 18 to 232 pmol/L. Com-
mon carotid artery IMT ranged from 0.43 to 0.97 mm.
CRP was significantly associated with measures of obesity:
BMI, waist and hip circumferences, and WHR (Table 2).
Associations with CRP were stronger for BMI and waist and
hip circumferences than for WHR (r50.54 for BMI, r50.55
for waist circumference, r50.53 for hip circumference, and
r50.33 for WHR, all adjusted for age). After adjustment for
BMI, hip circumference and WHR were no longer associated
with CRP, whereas waist circumference still was. We next
visualized this relationship between BMI, WHR, and CRP by
subdividing the study population by the median BMI (23.9
kg/m2) and WHR (0.77) (the Figure, geometric means). BMI
explained 29.7% of the variance of CRP; waist circumfer-
ence, 31.3%; hip circumference, 28.7%; and WHR, 11.4%,
after adjustment for age.
The other variables included in or associated with the
insulin resistance syndrome were also significantly associated
with CRP: blood pressure, insulin, HDL cholesterol, triglyc-
erides, apolipoprotein A1 (inversely), PAI-1 antigen, and tPA
antigen (Table 3). No associations were found with glucose or
with total and LDL cholesterol, whereas an association with
apolipoprotein B was present. Separate analyses after exclu-
sion of subjects with levels of CRP .10 mg/L did not affect
the results (data not shown).
After controlling for BMI, the associations between CRP
and variables of the insulin resistance syndrome disappeared
except for the association with PAI-1 antigen, although there
was a substantial decline in the magnitude of this association
(Table 3). Controlling for waist circumference gave the same
results, whereas controlling for hip circumference decreased
the described associations to a somewhat smaller extent.
Controlling for WHR, on the other hand, had only a small
influence on the described associations (data not shown). To
evaluate whether the clustering of variables belonging to the
insulin resistance syndrome might be a reflection of a general
acute-phase response, associations between measures of in-
sulin resistance (insulin and HOMA) and the other variables
of the insulin resistance syndrome were adjusted for CRP.
This adjustment did not modify the relation between insulin,
HOMA, and the other variables (data not shown).
Measures of obesity and CRP in premenopausal and
postmenopausal women separately are shown in Table 4.
CRP did not differ significantly between premenopausal and
postmenopausal women. Age-adjusted geometric means were
0.61 and 0.71 mg/L respectively (15% increase with meno-
pause, 95% CI, –15% to 45%). Because menopause may be
associated with changes in measures of obesity, we adjusted
for these variables, which slightly influenced the results.
Postmenopausal women had an age-adjusted level of choles-
terol of 6.48 mmol/L versus 5.89 mmol/L in premenopausal
women (10% difference; 95% CI, 5% to 14%). PAI-1 antigen
increased with menopause, but the difference lacked statisti-
cal significance. In premenopausal women, the age-adjusted
geometric mean of PAI-1 antigen was 52.9 ng/mL versus
61.1 ng/mL in postmenopausal women (13% increase with
menopause; 95% CI, –8% to 33%). Because cholesterol and
PAI-1 antigen are known to increase with menopause, these
results indicate a correct selection of menopausal groups. The
associations between CRP on the one hand and both measures
of obesity and other variables of the insulin resistance
syndrome on the other were found to be identical when
examined in premenopausal and postmenopausal women
separately (data not shown).
CRP was significantly associated with common carotid
artery IMT. After stratification by smoking status, associa-
tions between CRP and common carotid artery IMT appeared
to be present in ever-smokers only (Table 5). Common
carotid artery IMT explained 3.7% of the variance of CRP
after adjustment for age.
Discussion
Our results indicate that in healthy, middle-aged women,
CRP is strongly associated with measures of obesity. CRP
was associated with BMI and waist and hip circumferences
but not with WHR after adjustment for BMI. CRP was also
associated with other variables included in the insulin resis-
tance syndrome. After controlling for BMI, however, the
associations disappeared. Although in this population CRP
was associated with common carotid artery IMT in ever-
Levels of CRP (mg/L) according to BMI and WHR in 186
women. Values are geometric means.
TABLE 2. Regression Coefficients* for ln CRP as the Dependent Variable and
Measures of Obesity as Independent Variables in 186 Women
Adjusted for Age Adjusted for Age1BMI
b* 95% CI b* 95% CI
BMI, 1 kg/m2 0.14† 0.11 to 0.18 z z z z z z
Waist circumference, 10 cm 0.62† 0.48 to 0.75 0.39‡ 0.11 to 0.67
Hip circumference, 10 cm 0.65† 0.50 to 0.80 0.29 20.051 to 0.67
WHR, 0.05 0.34† 0.20 to 0.49 0.12 20.021 to 0.26
b indicates regression coefficient.
*An increase of the independent variable by 1 unit is associated with an increase of CRP by a factor
of eb.
Regression significant at the ‡0.01 and †0.001 levels, respectively (all 2-tailed).
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smokers, measures of obesity explained a much larger part of
the variance of CRP than did carotid artery IMT.
One hypothesis explaining these results is that adipose
tissue might be the common antecedent of both CRP and
insulin resistance. The associations between CRP and vari-
ables of the insulin resistance syndrome may thus be due to
the association of BMI with both insulin resistance and the
acute-phase response. This idea is consistent with experimen-
tal evidence indicating that adipocytes produce tumor necro-
sis factor (TNF)-a.33 TNF-a induces interleukin-6 (IL-6)
synthesis,34 a prime regulator of CRP synthesis.35,36 Addi-
tional support for this hypothesis comes from the observation
that weight reduction leads to a decrease of TNF-a mRNA
expression37 and of serum levels of TNF-a in diabetic
subjects.38 We found that CRP was strongly related to BMI
and to waist and hip circumferences separately, but less to
WHR. These results are compatible with previous studies, in
which BMI but not WHR was related to TNF-a expression or
TNF-a levels.33,39 However, after adjustment for BMI, waist
circumference was still related to CRP, whereas hip circum-
ference was not. This suggests that abdominal fat deposition
is most important in inducing inflammation.
Associations between CRP concentrations and fasting se-
rum insulin concentrations, which persisted after adjustment
for BMI, have been observed in a population of male patients
with angina pectoris.18 In addition, in healthy, middle-aged
men, relationships between CRP and cardiovascular risk
factors like HDL cholesterol and triglycerides persisted after
adjustment for BMI.14 One possible explanation for these
discrepant results might be that the relationships between
obesity, the insulin resistance syndrome, and the acute-phase
response are different between men and women. Support for
this hypothesis comes from the observation that sex steroids
influence the metabolic activity of adipose tissue.40 Addition-
TABLE 3. Regression Coefficients* for ln CRP as the Dependent Variable and Clinical and
Biochemical Characteristics as Independent Variables in 186 Women
Adjusted for Age Adjusted for Age1BMI
b* 95% CI b* 95% CI
Systolic blood pressure, 10 mm Hg 0.16† 0.057 to 0.27 0.025 20.071 to 0.12
Diastolic blood pressure, 10 mm Hg 0.20† 0.043 to 0.35 0.029 20.11 to 0.17
Glucose, 1 mmol/L 0.23 20.055 to 0.51 20.069 20.32 to 0.18
Insulin, 10 picomol/L 0.11‡ 0.057 to 0.16 0.024 20.025 to 0.074
HOMA, 5 picomol3mmol/L2§ 0.18‡ 0.089 to 0.26 0.028 20.058 to 0.12
Cholesterol, 1 mmol/L 0.11 20.045 to 0.26 0.080 20.050 to 0.21
HDL cholesterol, 0.5 mmol/L 20.37‡ 20.56 to 20.17 20.092 20.28 to 0.093
LDL cholesterol, 1 mmol/L 0.15 20.020 to 0.31 0.090 20.051 to 0.23
Triglycerides, 1 mmol/L 0.64‡ 0.38 to 0.90 0.23 20.027 to 0.49
Apolipoprotein A1, 10 mg/dL 20.063\ 20.11 to 20.015 20.027 20.068 to 0.015
Apolipoprotein B, 10 mg/dL 0.078\ 0.021 to 0.14 0.029 20.022 to 0.080
PAI-1 antigen, 1 ng/mL# 0.65‡ 0.45 to 0.84 0.30\ 0.082 to 0.51
tPA antigen, 1 ng/mL 0.13‡ 0.067 to 0.19 0.052 20.005 to 0.11
b indicates regression coefficient.
*An increase of the independent variable by 1 unit is associated with an increase of CRP by a factor of eb.
§HOMA5fasting insulin3fasting glucose/22.5.
#PAI-1 was ln-transformed to obtain a better-model fit as assessed by residual analysis; an increase of PAI-1 by
1% yields an increase of CRP by b%.
Regression significant at the †0.05, \0.01, and ‡0.001 levels, respectively (all 2-tailed).
TABLE 4. Measures of Obesity and CRP in Premenopausal and
Postmenopausal Women
Premenopausal (n593) Postmenopausal (n593)
Mean SE Mean SE
Age, y 50.6 0.24 51.1 0.24
BMI, kg/m2* 24.7 0.41 25.0 0.41
Waist circumference, cm* 81.3 1.00 81.6 0.99
Hip circumference, cm* 105.3 0.90 106.1 0.89
WHR, cm/cm* 0.77 0.005 0.77 0.005
CRP, mg/L*† 0.61 0.49 to 0.76 0.71 0.58 to 0.88
CRP, mg/L†‡ 0.62 0.52 to 0.74 0.69 0.58 to 0.84
*Adjusted for age.
†Geometric mean (95% CI) are shown for CRP because its distribution is highly skewed.
‡Adjusted for age and BMI.
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ally, the described studies differ from ours in that those
subjects were likely to suffer from more pronounced athero-
sclerosis because they were male or suffering from angina
pectoris. Atherosclerosis might have spuriously induced the
relation between CRP and other cardiovascular risk factors.
Because in our population women had a low burden of
atherosclerosis, as estimated from carotid artery IMT, the
potential for confounding by atherosclerosis in our study is
less likely.
Associations between measures of insulin resistance and
other variables included in the insulin resistance syndrome
were not attenuated by adjusting for CRP levels. Therefore,
our data do not suggest that the clustering of variables
belonging to the insulin resistance syndrome might be a
reflection of a general acute-phase response.16 Also, because
the association between insulin resistance and measures of
obesity was not affected by adjustment for CRP, our data do
not support the hypothesis that adipose-tissue–derived cyto-
kines may mediate the relation between obesity and the
insulin resistance syndrome.17,33,37,39 However, this hypothe-
sis encompasses a causal role for TNF-a; therefore, this
inference might have been more valid had we adjusted for
TNF-a instead of CRP.
The selection of premenopausal and postmenopausal
women is likely to be accurate, as reflected by an age-
adjusted increase of cholesterol of 10%, which is in agree-
ment with other studies.41,42 We did not find a clear influence
of menopause on CRP levels. Both age- and age-and-BMI–
adjusted levels of CRP were slightly higher in postmeno-
pausal (0.71 mg/L) than in premenopausal (0.61 mg/L)
women, but this 15% difference was not statistically signifi-
cant. This result can probably be attributed to the large
variation of this measure. To the best of our knowledge, no
published data on the association between menopause and
CRP levels are available from other studies. Estrogen replace-
ment therapy in postmenopausal women has been shown to
lower TNF-a43 and acute-phase reactants other than CRP.44
Experimental data suggest an inhibitory effect of estrogens on
IL-6 gene expression.45 Recent data from the Cardiovascular
Health Study, however, suggest an increase of CRP with
hormone replacement therapy.46 Further studies are needed to
address the association between inflammation, estrogens, and
menopause.
We are the first to describe an association between CRP
and common carotid artery IMT in healthy, middle-aged
women, which association was limited to ever-smokers (Ta-
ble 4). In a study by Tracy et al15 in a population of elderly
men and women, CRP was not related to internal carotid wall
thickness but was related to ankle-arm index in ever-smokers
only Data from the MRFIT (Multiple Risk Factor Interven-
tion Trial) study also show a stronger association of CRP with
coronary heart disease deaths in middle-aged male smokers
than in nonsmokers, as defined at baseline.8 Taken together,
these and the present data suggest that CRP may mark
permanent, underlying vascular damage due in part to smok-
ing. This may explain why the associations between inflam-
mation and atherosclerosis are more pronounced not only in
current but also in former smokers. In the Physicians’ Health
Study, however, smoking did not modify the relation between
CRP and the risk of cardiovascular events.7
Some issues of our study need to be addressed. First, we
did not measure exposure to infectious agents such as
Helicobacter pylori and Chlamydia pneumoniae, which may
be weak determinants of CRP levels.12,17 However, it appears
unlikely that exposure to these agents would confound the
association between BMI and CRP level. Second, in this
study we measured atherosclerosis at only 1 location in the
vascular system. Although we assume that common carotid
artery IMT is a measure of generalized atherosclerosis,28
assessment of the degree of atherosclerosis might have been
more accurate had we used measurements at multiple loca-
tions. Finally, this study was conducted in healthy, middle-
aged women without clinical cardiovascular disease, no
medication use, and a low, current exposure to tobacco.
Smoking and atherosclerosis are potential determinants of
CRP, and therefore, the choice of our population facilitates
the investigation of other factors associated with CRP.
However, in this population, ever-smoking was also found to
modify the association between CRP and atherosclerosis.
In summary, our results indicate that adipose tissue is
strongly associated with CRP in healthy, middle-aged
women. In this population with a low burden of atheroscle-
rosis and current smoking, BMI accounts for the association
between CRP and variables of the insulin resistance syn-
drome. Because inflammatory mediators may be directly
involved in atherogenesis, these results suggest an important
mechanism through which obesity might affect the risk of
coronary heart disease. Further studies should determine
whether losing weight ameliorates the inflammatory state.
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TABLE 5. Regression Coefficients* for ln CRP as the Dependent Variable and Common
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